Myriad Genetics Inc. now has a P/E ratio of 90.5. For a complete fundamental analysis analysis of Myriad Genetics Inc., check out Equities.com’s Stock Valuation Analysis report for MYGN. Myriad Genetics Inc is a molecular diagnostic …
Myriad Genetics, Inc. (MYGN) stock moved with shift of 3.84% in the past week. …
Get Myriad Genetics Inc. alerts: Myriad Genetics, Inc. (MYGN) opened at 28.96 …
Collecting that bid as the premium represents a 6% return against the $24 commitment, or a 12.1% annualized rate of return (at Stock Options Channel we call this the YieldBoost). Selling a put does not give an investor access to …
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk …
(NASDAQ:MYGN). First Tru Advisors Ltd Partnership has invested 0.07% in Myriad Genetics, Inc. It has underperformed by 54.17% the S&P500. Two equities research analysts have rated the stock with a sell rating, eight have given a hold …
The stock’s market capitalization is 1.98B, it has a 52-week low of 15.15 and a 52-week high of 29.30. The share price of the company (NASDAQ:MYGN) was up +0.07%, with a high of 29.16 during the day and the volume of Myriad …
SmarTrend identified an Uptrend for Myriad Genetics (NASDAQ:MYGN) on May 3rd, 2017 at $21.49. In approximately 3 months, Myriad Genetics has returned 30.17% as of today's recent price of $27.98. In the past 52 weeks, shares of …
On Aug 11, we issued an updated research report on Salt Lake City, UT-based molecular diagnostics provider, Myriad Genetics, Inc.MYGN. The company currently ... continues to be a major dampener for the stock. Management fears …
Myriad Genetics Inc. (MYGN) traded on unusually high volume on Aug. 11, as the stock gained 2.06% to close at $27.76. On the day, Myriad Genetics Inc. saw 1.56 million shares trade hands on 11,238 trades. Considering that the stock